A study that investigated the impact of genetic and pharmacologic manipulation of the PTEN pathway in a ribonucleic acid (RNA) interference mouse model of HER2 metastatic breast cancer shows that the disease progression from PTEN silencing is related to elevated signaling through PI3K and MAPK (MEK) pathways (18). This evidence concerns the gene ERBB2 and breast carcinoma.